Vyuhpharma

Pfizer *(FDA, Approval)*

Pfizer’s ADCETRIS combination regimen for the treatment of relapsed/refractory diffuse large B-cell lymphoma has received approval from the US FDA

Genetech *(FDA, Approval)*

FDA has approved Genentech's Evrysdi tablet as the first and only tablet for treating SMA

Sanofi-Aventis *(FDA, Approval)*

The FDA has approved Sanofi-Aventis' Merilog, the first rapid-acting insulin biosimilar, indicated for glycemic control in both adult and pediatric patients with diabetes mellitus

---

SpringWorks Therapeutics *(FDA, Approval)*

SpringWorks' GOMEKLI received FDA approval for adults and children with NF1-PN

Glenmark + Cosmo *(MHRA, Approval)*

Cosmos + Glenmark received MHRA approval to market Winlevi in the UK for the treatment of acne vulgaris in patients (>12 yrs age)

Vyuhpharma

CSL + Arcturus Therapeutics *(EU, MAA)*

CSL + Arcturus' KOSTAIVE, the first self-amplifying mRNA COVID-19 vaccine, received EU marketing approval

---

Astellas *(FDA, Label expansion)*

FDA approved Astellas IZERVAY expanded use for the treatment of GA secondary to AMD

Nektar Therapeutics *(FDA, FTD)*

Nektar's rezpegaldesleukin received FDA FTD for the treatment of adult and pediatric (12 yrs) patients with moderate-to-severe atopic dermatitis

---

Lundbeck *(FDA, FTD)*

Lundbeck received FDA FTD for amlenetug for the treatment of MSA

Pleopharma *(FDA, FTD)*

Pleopharma's PP-01, a potential first-in-class treatment, received FDA's FTD for the mitigation of cannabis withdrawal syndrome in patients with cannabis use disorder

Vyuhpharma

OnCusp Therapeutics *(FDA, FTD)*

OnCusp's CUSP06 received FDA's FTD for platinum-resistant ovarian cancer

---

Tempest therapeutics *(FDA, FTD)*

Tempest's Amezalpat received FDA's FTD for the treatment of patients with HCC

Glenmark *(US, Launch)*

Glenmark launched Evoclin's equivalent, clindamycin phosphate foam, 1% in the US

AbbVie + Xilio *(Collaboration)*

AbbVie reached collaboration and option-to-license agreement with Xilio to develop novel tumor-activated mAb immunotherapies using T-cell engagers, leveraging Xilio's proprietary technology

---

IDEAYA + Gilead *(Collaboration)*

IDEAYA entered clinical collaboration and supply agreement with Gilead for IDE397 in combination with Trodelvy in MTAP-deletion NSCLC

Vyuhpharma

DAAN + LigaChem *(Licensing agreement)*

DAAN signed an exclusive licensing agreement with LigaChem for ADC development of novel tumor-targeting mAb in solid tumor patients

---

Boehringer Ingelheim *(Clinical trials)*

Topline Ph 3 FIBRONEER data on nerandomilast for the treatment of progressive pulmonary fibrosis met its endpoints; Boehringer Ingelheim to initiate NDA submission to FDA and other health authorities worldwide

---

Pfizer + Astellas *(Clinical trials result)*

Pfizer + Astellas' PADCEV combined with KEYTRUDA demonstrates long-term efficacy in the first-line treatment of la/mUC

Pfizer *(Clinical trials result)*

Pfizer reported Ph 3 results of TALZENNA combined with XTANDI, with clinically significant improvement in patients with mCRPC regardless of HRR gene mutations